The long-term goal of the cervical cancer SPORE at Johns Hopkins is to reduce the incidence, morbidity, and mortality related to cervical cancers via rapid translation of scientific advance. SPORE projects are translational in nature and aim to develop intervention strategies for the prevention and treatment for cervical cancer.
Project 1: Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer globally
Project 2: Electroporation delivery of pNGVL4aCRTE6E7L2 DNA for treatment of HPV16+ CIN2/3 patients.
Project 3: A Phase I safety and immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection.
The organization and timetable of the SPORE projects are summarized in the charts below. Table 1 indicates the research areas addressed by each SPORE project. A translational timeline for each project is shown in Table 2, demonstrating the translational scope of each project along a research/clinical progress continuum.
Table 1: Components of the Cervical Cancer SPORE
Table 2: Translational Scope of Research in the Cervical Cancer SPORE
